[A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].
Identifieur interne : 002468 ( PubMed/Curation ); précédent : 002467; suivant : 002469[A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].
Auteurs : De-Xian Yu [République populaire de Chine] ; Qing Chen ; Li-Lan Zhang ; Yi Liu ; Zhi-Ai Yu ; Zhi-Feng Li ; Li-Ping Zhang ; Gui-Fang Hu ; Zhao-Jun Duan ; Xin-Wei Chu ; Bin Zhang ; Shou-Yi Yu ; Yun-De HouSource :
- Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology [ 1003-9279 ] ; 2005.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Adulte, Anticorps antiviraux (sang), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Humains, Immunoglobuline G (sang), Immunoglobuline M (sang), Infections de l'appareil respiratoire (), Infections de l'appareil respiratoire (sang), Infections de l'appareil respiratoire (virologie), Interféron alpha (administration et posologie), Interféron alpha (usage thérapeutique), Jeune adulte, Méthode en double aveugle, Protéines recombinantes, Résultat thérapeutique, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (sang), Virus du SRAS (), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Antiviraux, Interféron alpha.
- immunologie : Virus du SRAS.
- sang : Anticorps antiviraux, Immunoglobuline G, Immunoglobuline M, Infections de l'appareil respiratoire, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Interféron alpha.
- virologie : Infections de l'appareil respiratoire.
- Administration par voie nasale, Adulte, Humains, Infections de l'appareil respiratoire, Jeune adulte, Méthode en double aveugle, Protéines recombinantes, Résultat thérapeutique, Syndrome respiratoire aigu sévère, Virus du SRAS.
English descriptors
- KwdEn :
- Administration, Intranasal, Adult, Antibodies, Viral (blood), Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Double-Blind Method, Humans, Immunoglobulin G (blood), Immunoglobulin M (blood), Interferon alpha-2, Interferon-alpha (administration & dosage), Interferon-alpha (therapeutic use), Recombinant Proteins, Respiratory Tract Infections (blood), Respiratory Tract Infections (prevention & control), Respiratory Tract Infections (virology), SARS Virus (drug effects), SARS Virus (immunology), Severe Acute Respiratory Syndrome (blood), Severe Acute Respiratory Syndrome (chemically induced), Severe Acute Respiratory Syndrome (prevention & control), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha.
- chemical , blood : Antibodies, Viral, Immunoglobulin G, Immunoglobulin M.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha.
- blood : Respiratory Tract Infections, Severe Acute Respiratory Syndrome.
- chemically induced : Severe Acute Respiratory Syndrome.
- drug effects : SARS Virus.
- immunology : SARS Virus.
- prevention & control : Respiratory Tract Infections, Severe Acute Respiratory Syndrome.
- virology : Respiratory Tract Infections.
- Administration, Intranasal, Adult, Double-Blind Method, Humans, Interferon alpha-2, Recombinant Proteins, Treatment Outcome, Young Adult.
Abstract
To study the preventive effect of recombinant human interferon alpha-2b for nasal spray against SARS and other common respiratory viral infections by serum-epidemiological method.
PubMed: 16261200
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002468
Links to Exploration step
pubmed:16261200Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].</title><author><name sortKey="Yu, De Xian" sort="Yu, De Xian" uniqKey="Yu D" first="De-Xian" last="Yu">De-Xian Yu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, The Southern Medical University, Guangzhou 510515, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Epidemiology, The Southern Medical University, Guangzhou 510515</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Qing" sort="Chen, Qing" uniqKey="Chen Q" first="Qing" last="Chen">Qing Chen</name></author><author><name sortKey="Zhang, Li Lan" sort="Zhang, Li Lan" uniqKey="Zhang L" first="Li-Lan" last="Zhang">Li-Lan Zhang</name></author><author><name sortKey="Liu, Yi" sort="Liu, Yi" uniqKey="Liu Y" first="Yi" last="Liu">Yi Liu</name></author><author><name sortKey="Yu, Zhi Ai" sort="Yu, Zhi Ai" uniqKey="Yu Z" first="Zhi-Ai" last="Yu">Zhi-Ai Yu</name></author><author><name sortKey="Li, Zhi Feng" sort="Li, Zhi Feng" uniqKey="Li Z" first="Zhi-Feng" last="Li">Zhi-Feng Li</name></author><author><name sortKey="Zhang, Li Ping" sort="Zhang, Li Ping" uniqKey="Zhang L" first="Li-Ping" last="Zhang">Li-Ping Zhang</name></author><author><name sortKey="Hu, Gui Fang" sort="Hu, Gui Fang" uniqKey="Hu G" first="Gui-Fang" last="Hu">Gui-Fang Hu</name></author><author><name sortKey="Duan, Zhao Jun" sort="Duan, Zhao Jun" uniqKey="Duan Z" first="Zhao-Jun" last="Duan">Zhao-Jun Duan</name></author><author><name sortKey="Chu, Xin Wei" sort="Chu, Xin Wei" uniqKey="Chu X" first="Xin-Wei" last="Chu">Xin-Wei Chu</name></author><author><name sortKey="Zhang, Bin" sort="Zhang, Bin" uniqKey="Zhang B" first="Bin" last="Zhang">Bin Zhang</name></author><author><name sortKey="Yu, Shou Yi" sort="Yu, Shou Yi" uniqKey="Yu S" first="Shou-Yi" last="Yu">Shou-Yi Yu</name></author><author><name sortKey="Hou, Yun De" sort="Hou, Yun De" uniqKey="Hou Y" first="Yun-De" last="Hou">Yun-De Hou</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16261200</idno><idno type="pmid">16261200</idno><idno type="wicri:Area/PubMed/Corpus">002468</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002468</idno><idno type="wicri:Area/PubMed/Curation">002468</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002468</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].</title><author><name sortKey="Yu, De Xian" sort="Yu, De Xian" uniqKey="Yu D" first="De-Xian" last="Yu">De-Xian Yu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, The Southern Medical University, Guangzhou 510515, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Epidemiology, The Southern Medical University, Guangzhou 510515</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Qing" sort="Chen, Qing" uniqKey="Chen Q" first="Qing" last="Chen">Qing Chen</name></author><author><name sortKey="Zhang, Li Lan" sort="Zhang, Li Lan" uniqKey="Zhang L" first="Li-Lan" last="Zhang">Li-Lan Zhang</name></author><author><name sortKey="Liu, Yi" sort="Liu, Yi" uniqKey="Liu Y" first="Yi" last="Liu">Yi Liu</name></author><author><name sortKey="Yu, Zhi Ai" sort="Yu, Zhi Ai" uniqKey="Yu Z" first="Zhi-Ai" last="Yu">Zhi-Ai Yu</name></author><author><name sortKey="Li, Zhi Feng" sort="Li, Zhi Feng" uniqKey="Li Z" first="Zhi-Feng" last="Li">Zhi-Feng Li</name></author><author><name sortKey="Zhang, Li Ping" sort="Zhang, Li Ping" uniqKey="Zhang L" first="Li-Ping" last="Zhang">Li-Ping Zhang</name></author><author><name sortKey="Hu, Gui Fang" sort="Hu, Gui Fang" uniqKey="Hu G" first="Gui-Fang" last="Hu">Gui-Fang Hu</name></author><author><name sortKey="Duan, Zhao Jun" sort="Duan, Zhao Jun" uniqKey="Duan Z" first="Zhao-Jun" last="Duan">Zhao-Jun Duan</name></author><author><name sortKey="Chu, Xin Wei" sort="Chu, Xin Wei" uniqKey="Chu X" first="Xin-Wei" last="Chu">Xin-Wei Chu</name></author><author><name sortKey="Zhang, Bin" sort="Zhang, Bin" uniqKey="Zhang B" first="Bin" last="Zhang">Bin Zhang</name></author><author><name sortKey="Yu, Shou Yi" sort="Yu, Shou Yi" uniqKey="Yu S" first="Shou-Yi" last="Yu">Shou-Yi Yu</name></author><author><name sortKey="Hou, Yun De" sort="Hou, Yun De" uniqKey="Hou Y" first="Yun-De" last="Hou">Yun-De Hou</name></author></analytic><series><title level="j">Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology</title><idno type="ISSN">1003-9279</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Humans</term><term>Immunoglobulin G (blood)</term><term>Immunoglobulin M (blood)</term><term>Interferon alpha-2</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (therapeutic use)</term><term>Recombinant Proteins</term><term>Respiratory Tract Infections (blood)</term><term>Respiratory Tract Infections (prevention & control)</term><term>Respiratory Tract Infections (virology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (blood)</term><term>Severe Acute Respiratory Syndrome (chemically induced)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Anticorps antiviraux (sang)</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Humains</term><term>Immunoglobuline G (sang)</term><term>Immunoglobuline M (sang)</term><term>Infections de l'appareil respiratoire ()</term><term>Infections de l'appareil respiratoire (sang)</term><term>Infections de l'appareil respiratoire (virologie)</term><term>Interféron alpha (administration et posologie)</term><term>Interféron alpha (usage thérapeutique)</term><term>Jeune adulte</term><term>Méthode en double aveugle</term><term>Protéines recombinantes</term><term>Résultat thérapeutique</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (sang)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Respiratory Tract Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Respiratory Tract Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term><term>Immunoglobuline M</term><term>Infections de l'appareil respiratoire</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections de l'appareil respiratoire</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Double-Blind Method</term><term>Humans</term><term>Interferon alpha-2</term><term>Recombinant Proteins</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Humains</term><term>Infections de l'appareil respiratoire</term><term>Jeune adulte</term><term>Méthode en double aveugle</term><term>Protéines recombinantes</term><term>Résultat thérapeutique</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To study the preventive effect of recombinant human interferon alpha-2b for nasal spray against SARS and other common respiratory viral infections by serum-epidemiological method.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16261200</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1003-9279</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology</Title><ISOAbbreviation>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].</ArticleTitle><Pagination><MedlinePgn>216-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the preventive effect of recombinant human interferon alpha-2b for nasal spray against SARS and other common respiratory viral infections by serum-epidemiological method.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A randomized, placebo-controlled, double-blind field trial study in populations with 14,391 persons from SARS prevalent cities or provinces in China during May-Jun, 2003 and Dec-Apr, 2004. Interferon alpha-2b was given twice per day, once 9 x 10(5) IU by nasal spray for 5 days. Serum samples were taken at 15 days after last administration. Serological tests included SARS IgG antibody and IgM antibodies against influenza B, parainfluenza virus types 1-3, adenovirus type 3, 7 and respiratory syncytial virus by using commercial ELISA kits.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No statistically significant difference in serum SARS IgG antibody positive rate was found between the interferon and control groups among 2,757 serum samples. On the other hand, after using interferon, all four respiratory viruses (parainfluenza virus types 1-3 influenza B, adenovirus types 3, 7 and respiratory syncytial virus) in interferon group had lower IgM antibody positive rates than those in control group. Among them there were statistically significant differences between the interferon and control groups for parainfluenza virus, influenza B and adenovirus. The preventive efficacy of interferon against four respiratory viruses was different, from high to low, the rank was Flu B (66.76%), parainfluenza types 1-3 (66.75%), RSV (39.61%) and adenovirus (32.86%). The average preventive efficacy was 50.27%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The recombinant human interferon alpha-2b for nasal spray could decrease the rates of common respiratory viruses infection in the selected population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>De-xian</ForeName><Initials>DX</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, The Southern Medical University, Guangzhou 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li-lan</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhi-ai</ForeName><Initials>ZA</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhi-feng</ForeName><Initials>ZF</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li-ping</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Gui-fang</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Zhao-jun</ForeName><Initials>ZJ</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Xin-wei</ForeName><Initials>XW</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shou-yi</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Yun-de</ForeName><Initials>YD</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi</MedlineTA><NlmUniqueID>9602873</NlmUniqueID><ISSNLinking>1003-9279</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16261200</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16261200
|texte= [A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16261200" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |